
Publication|Articles|July 7, 2025
Supplements and Featured Publications
- Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Listen
0:00 / 0:00
Advertisement
This clinical brief is supported by Bausch + Lomb.
This AJMC® Clinical Brief provides a primer on dry eye disease (DED) diagnosis, pathophysiology, and treatment, highlights a DED treatment, and discusses real-world data about patient treatment satisfaction.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
CHEST 2025 Highlights: Future of Respiratory Vaccines and the Impact of Federal Funding Cuts
3
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
4
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
5












































